“Nano-Innovation Beyond Boundaries, Leading Human Health and Future Industries”
Through the two visions of “New Era Treatment” and “New Challenge,” ACENANO presents a path toward true future industry innovation that goes beyond existing limitations. We begin with constant questions about “the essence of healing” and “the new boundaries of industry.” The root of this innovation comes from our belief in the harmonious cycle between humanity and nature. We draw inspiration from nature and advance technology to improve human life. Across diverse industries such as medical, bio, energy, and environment, these fields converge on the ACENANO platform to create a new paradigm for a healthier, more sustainable, and safer society.
ACENANO dreams of a world where “everyone can enjoy a better life” through innovation that breaks down the boundaries between treatment and industry, health and the future, humanity and nature. At the heart of this journey lies our mission of “nano-innovation beyond boundaries” and our vision for sustainable growth together with global partners, customers, and future generations. ACENANO will continue to expand the boundaries of innovation and become a leading force of a new era that drives human health and future industries.
New Era Treatment embodies a vision that goes beyond simply improving treatment, aiming to completely transform humanity’s approach to disease and health. By overcoming the side effects and limitations of conventional treatments, natural substance-based new drugs and high-functionality biomaterials designed with nanotechnology enable safer, targeted, and personalized healing for humans.
This is not merely the development of a single pharmaceutical product, but the realization of a future medical ecosystem humanity has long dreamed of—one that prevents disease in advance and delivers maximum results with minimal resources.
Through New Challenge, ACENANO leads the future of industry—the convergence of unexplored fields and advanced technologies.
In areas that require humanity’s boldest challenges, such as all-solid-state batteries, semiconductors, aerospace, and environmental energy, our ultra-low-temperature nanotechnology and core materials platform become a new industrial standard.
Through core technology R&D that goes beyond existing limitations, open innovation, and global industry-academia-research collaboration, ACENANO will establish itself as a new center of future industries, not only in Korea but around the world.
Ultra-Fine Nano-Sizing
: Disperses natural and synthetic materials into nanoparticles at the 1–900 nm level, maximizing particle size control and surface area.
Application of Ultra-Low-Temperature Process Below -40°C
: Enables nano-sizing while preserving even heat-sensitive bioactive substances without damage, allowing mass production of high-functionality raw materials.
Chemical-Free and Additive-Free Grinding
: Processes materials through purely physical methods such as grinding, shearing, friction, and collision without chemical solvents or additives, ensuring high purity and stability.
Innovation in Drug Delivery System (DDS)
: Maximizes delivery efficiency to target tissues and cells, enhancing the absorption and efficacy of drugs and functional ingredients in the body.
Platform Technology
: Universally applicable across various industries, including food, cosmetics, pharmaceuticals, energy, and aerospace.
Overcoming the Limitations of Conventional Treatments
: Addresses issues associated with synthetic pharmaceuticals, such as toxicity, resistance, and low efficiency.
Uniqueness of Ultra-Low-Temperature Nano-Sizing Technology
: Minimizes the destruction of active ingredients in heat-sensitive raw materials during cryogenic processing, preserving the inherent functions of natural substances.
Leading the Market for New Drugs and Recombinant Therapeutics
: Replaces conventional synthetic drugs through the development of customized therapeutics based on bio and natural substances.
Creating Convergent New Markets
: Provides a foundation for creating new products that converge industries such as biohealth, wellness, personalized treatment, and high-functionality foods.
Innovation Based on Intellectual Property (IP)
: Builds technological and market entry barriers through core patents and numerous derivative patents.
Pharmaceuticals & Bio
: Drives disruptive innovation in emerging markets such as nano-sized natural substance-based new drugs, DDS formulations, and personalized therapeutics.
Cosmetics & Dermocosmetics
: Maximizes absorption and efficacy compared to conventional products by incorporating nano functional ingredients such as antioxidants, brightening agents, and anti-inflammatory components.
Food & Health Functional Foods
: Creates premium markets with high-absorption, high-functionality ingredients while responding to trends such as Clean Label and vegan products.
Energy, Batteries & Semiconductors
: Applies new technologies to advanced industries and secures new markets with heat-sensitive materials, high-purity nano powders, and other advanced materials.
Aerospace & Environment
: Develops nano materials for cryogenic and extreme environments, as well as next-generation functional new materials.
Global Originality in Cryogenic Nano-Sizing
: Holds a competitive advantage over the U.S., Europe, and Japan in terms of technological maturity and commercialization speed.
Global Certification and Regulatory Readiness
: Meets strict global standards such as Non-GMO, Clean Label, eco-friendly requirements, and microplastic regulations.
Scalability of Technology Licensing and Supply
: Facilitates exports and partnerships through open innovation with multiple global companies and B2B/B2C business models.
Future-Oriented Brand Value
: Enhances the company’s image as an innovative enterprise and increases its appeal for investment attraction and M&A in the global market.
IP and Patents
: Enables long-term exclusivity and licensing revenue through core patents and multiple derivative patents.
High-Cost and High-Difficulty Cryogenic Process
: Improves productivity and reduces unit costs through process automation, energy efficiency, and scale-up mass production technology development.
Clinical and Certification Barriers
: Secures clinical, safety, and efficacy data through government, industry, academic, and research collaboration, while accelerating global certification acquisition.
Market Education and Consumer Awareness
: Promotes the advantages of “natural + nano” convergence technology to experts and consumers, while strengthening marketing linked to K-Bio and K-Beauty.
Technology Imitation and Catch-Up
: Strengthens protection by keeping process know-how confidential, advancing the technology, continuously securing new derivative patents, and building a global patent network.
Core Technology for New Drugs and the Future Medical Industry
: A fundamental platform for next-generation therapeutics, including targeted therapy, personalized medicine, anti-aging, and disease prevention.
Pioneering Global New Industries and Frontier Markets
: A strategic technology that drives entry into new markets such as all-solid-state batteries, aerospace, and polar environments.
Shared Growth and Ecosystem Development
: Open innovation and shared growth through partnerships with large corporations, governments, academia, startups, and other stakeholders.
National and Global Future Growth Engine
: Securing a leading position across the “technology–market–policy” triangle by linking with government projects, international cooperation funds, and investment attraction.
Platformization
: As a versatile foundational technology expandable across various industries, it serves as a core engine for ACENANO’s long-term global sustainable growth.
ACENANO | CEO: Hyejun Jeon
[ Address ]
Seoul Office: Baeksan-Bluewin Building, 157 Jeongneung-ro, Seongbuk-gu, Seoul, Korea
Seoul R&D Center: 1F, APEXEL Nano Science Museum, 63 World Cup buk-ro, Mapo-gu, Seoul, Korea
GMP Factory: 97-87, Daejeon-gil, Songna-myeon, Buk-gu, Pohang-si, Gyeongsangbuk-do, Korea
Copyright (c) ACENANO., LTD. all right resrved.
